NanoViricides, Inc.
As of Oct 22, 2026, NanoViricides is in Stage 3, the topping phase, now in week 11 (since Aug 11, 2026). It closed at $1.39, 31.5% below its 52-week high and above its 200-day average, which is rising.
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NNVC early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NNVC among Biotechnology206th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …206 | NNVC | Stage 3 · wk 11 | 49 | −7.9% |
NanoViricides: quick answers
What stage is NanoViricides in?
As of Oct 22, 2026, NanoViricides (NNVC) is in Stage 3, the topping phase. It entered Stage 3 on Aug 11, 2026 and is in week 11. What the four stages mean
Is NanoViricides in an uptrend?
Its uptrend has stalled. NanoViricides is in Stage 3, the topping phase that follows an advance. It trades 8.4% above its 200-day average, which is rising.
How far is NanoViricides from its 52-week high?
NanoViricides closed at $1.39 on Oct 22, 2026, 31.5% below its 52-week high of $2.03. Its 52-week low is $0.85.
How has NanoViricides performed over the past year?
As of Oct 22, 2026, NanoViricides is down 6.1% over the past year and up 14.9% so far in 2026.
Which sector and industry is NanoViricides in?
NanoViricides is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.